JP Morgan Call 155 CHKP 15.11.202.../ DE000JK86ZR5 /
| 2024-06-14 12:48:29 PM | Chg.-0.07 | Bid1:30:31 PM | Ask1:30:31 PM | Underlying | Strike price | Expiration date | Option type |
|---|---|---|---|---|---|---|---|
| 1.17EUR | -5.65% | 1.17 Bid Size: 3,000 |
1.23 Ask Size: 3,000 |
Check Point Software... | 155.00 USD | 2024-11-15 | Call |
GlobeNewswire
1:30 PM
Phase 2 Findings Show Wugen’s Investigational Allogeneic CAR-T, WU-CART-007, Was Highly Effective an...
GlobeNewswire
1:00 PM
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-3...
GlobeNewswire
12:00 PM
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Tria...
GlobeNewswire
06-12
NKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at ...
GlobeNewswire
06-12
OSE Immunotherapeutics KOL Investor Webinar on the Therapeutic Landscape and Unmet Medical Needs in ...
GlobeNewswire
06-12
PDS Biotech Provides Data Update from Ongoing VERSATILE-002 Phase 2 Clinical Trial in Head and Neck ...
GlobeNewswire
06-11
Check Point Software Simplifies Cloud Application Security with AI-Powered WAFaaS
GlobeNewswire
06-11
Bright Peak Therapeutics Announces $90 Million in Series C Financing to Advance First-in-Class PD1-I...
GlobeNewswire
06-10
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annu...
GlobeNewswire
06-10
Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FD...
GlobeNewswire
06-06
Scientific Journal Reports Findings that Show LIXTE’s Lead Clinical Compound, LB-100, Increases Reco...
GlobeNewswire
06-06
Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European...
GlobeNewswire
06-06
CHECKPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating Checkpoint Therapeutics, Inc. on Beha...
GlobeNewswire
06-05
Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positiv...
GlobeNewswire
06-05
OSE Immunotherapeutics and Nantes University Hospital Present Positive Phase 1/2 Study Evaluating FR...
GlobeNewswire
06-04
DEADLINE TODAY: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losse...
GlobeNewswire
06-04
Indaptus Therapeutics to Present New Positive Data on Decoy20 at Next-Gen Immuno-Oncology Conference
GlobeNewswire
06-04
CKPT DEADLINE TOMORROW: ROSEN, A LEADING LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investor...
GlobeNewswire
06-03
Ascendis Pharma Presents New Data and Updated Results from Phase 1/2 IL-Believe Trial at ASCO 2024
GlobeNewswire
06-03
7 Hills Pharma Receives $4.7MM Grant to Advance First-in-class Cell/Gene Therapy Technology into the...
GlobeNewswire
06-03
DEADLINE ALERT for CKPT, OCGN, SOND, QDEL: Law Offices of Howard G. Smith Reminds Investors of Class...
GlobeNewswire
06-03
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ch...
